Preview

Diabetes mellitus

Advanced search

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus

https://doi.org/10.14341/2072-0351-5971

Abstract

Aims.
To conduct an analysis of modern antihyperglycemic prescription patterns in type 2 diabetes mellitus (T2DM).
Materials and methods.
Russian DM State registry was studied.
Results.
We obtained absolute and comparative data on use of insulin analogues, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 agonists in treatment of T2DM.
Conclusion.
Percentage of DPP-4 inhibitors and GLP-1 analogues in T2DM treatment patterns remains nominal and does not exceed0.2%, which is significantly lower than in the majority of other countries. Insulin analogues are prescribed considerably more frequentlyand currently appear to be the most promising agents for treatment of T2DM.

About the Author

Yury Ivanovich Suntsov
Endocrinology Research Centre, Moscow


References

1. International Diabetes Federation, Diabetes Atlas, 5th ed. International Diabetes Federation. 2011.

2. Шестакова МВ, Баллан Акил. Терапия двухфазным инсулином аспарт 30/70 (НовоМикс® 30) улучшает гликемический контроль у пациентов с сахарным диабетом 2 типа: данные российской когорты пациентов наблюдательной программы IMPROVE - программы по изучению безопасности и эффективности двухфазного инсулина аспарт 30 в рутинной клинической практике. Сахарный диабет. 2010;(1):92-101.

3. Дедов ИИ, Шестакова МИ, Сунцов ЮИ, Ягудина РИ, Крысанов ИС, Куликов АЮ, Аринина ЕЕ. Фармакоэкономическое моделирование отдаленных результатов лечения сахарного диабета 2 типа у пациентов, получающих современные аналоги инсулинов по сравнению с терапией пероральными сахароснижающими препаратами. Сахарный диабет. 2010;(1):102-110.

4. Сунцов ЮИ, Шестакова МВ. Сравнительная характеристика затрат на лечение СД2 традиционными сахароснижающими средствами и комбинированной терапии Вилдаглиптином. Поликлиника. 2011;(1):2-6.

5. Plank J, Bodenlenz M, Sinner F, Magnes C, Görzer E, Regittnig W, Endahl LA, Draeger E, Zdravkovic M, Pieber TR. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005 May;28(5):1107-1112.

6. Dornhorst A, Lüddeke HJ, Sreenan S, Koenen C, Hansen JB, Tsur A, Landstedt-Hallin L. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract. 2007 Mar;61(3):523-528.

7. Goodall G, Jendle JH, Valentine WJ, Munro V, Brandt AB, Ray JA, Roze S, Foos V, Palmer AJ. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting. Int J Clin Pract. 2008 Jun;62(6):869-876.

8. Dalla Man C, Bock G, Giesler PD, Serra DB, Ligueros Saylan M, Foley JE, Camilleri M, Toffolo G, Cobelli C, Rizza RA, Vella A. Dipeptidyl Peptidase 4 inhibition by Vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. Diabetes Care. 2009 Jan;32(1):14-18. Epub 2008 Oct 17.

9. American Diabetes Association: Standards of medical care in diabetes-2008 (Position Statement). Diabetes Care. 2008;31(Suppl. 1): S12-54.

10. Forst T, Pfützner A, Flacke F, Krasner A, Hohberg C, Tarakci E, Pichotta P, Forst S, Steiner S. Postprandial Vascular Effects of VIAject Compared With Insulin Lispro and Regular Human Insulin in Patients With Type 2 Diabetes. Diabetes Care. 2010 Jan;33(1):116-120. Epub 2009 Oct 6.


Review

For citations:


Suntsov Yu.I. Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus. Diabetes mellitus. 2012;15(1):6-9. (In Russ.) https://doi.org/10.14341/2072-0351-5971

Views: 52112


ISSN 2072-0351 (Print)
ISSN 2072-0378 (Online)